MENS
Jyong Biotech Ltd.
$2.17
-0.46%
$165.7M
No data for this timeframe.
Vol
Market Cap$165.7M
Cap SizeMicro Cap
SEC Reports3
Recent Activity
May 15, 2026
SEC
Jyong Biotech filed its FY2025 annual report on Form 20-F, a routine regulatory milestone. The press release contains no
PRESS-RELEASE — Impact 2/10
May 15, 2026
earnings
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
<p align="justify">New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (N
May 15, 2026
SEC
Jyong Biotech's FY2025 20-F reveals a pre-revenue biotech in severe financial distress. The company has a net loss of $4
20-F — Impact 8/10
Apr 21, 2026
SEC
The court denied a motion for default judgment against MENS USA LLC and granted the company's request to vacate a clerk'
COURT-RULING — Impact 3/10
Mar 31, 2026
Event
Ricky R. Franklin v. MENS USA LLC doing business as MENSUSA.COM
Court ruling from District Court, N.D. Georgia. Docket: 1:25-cv-03930
Latest Reports
NEUTRAL
PRESS-RELEASE
2/10
Jyong Biotech filed its FY2025 annual report on Form 20-F, a routine regulatory milestone. The press release contains no
May 15, 2026
BEARISH
20-F
8/10
Jyong Biotech's FY2025 20-F reveals a pre-revenue biotech in severe financial distress. The company has a net loss of $4
May 15, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
PRESS-RELEASE
2/10
Jyong Biotech filed its FY2025 annual report on Form 20-F, a routine regulatory milestone. The press
May 15, 2026
BEARISH
20-F
8/10
Jyong Biotech's FY2025 20-F reveals a pre-revenue biotech in severe financial distress. The company
May 15, 2026
NEUTRAL
COURT-RULING
3/10
The court denied a motion for default judgment against MENS USA LLC and granted the company's reques
Apr 21, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 15, 2026
earnings
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
<p align="justify">New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a
Apr 28, 2026
other
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
<p align="justify">New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”),
Mar 31, 2026
Enforcement
Ricky R. Franklin v. MENS USA LLC doing business as MENSUSA.COM
Court ruling from District Court, N.D. Georgia. Docket: 1:25-cv-03930
Mar 27, 2026
other
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
<p align="justify">New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”),